NCT00253474已完成1 期
A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 8
研究概览
简要总结
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.
详细描述
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of PEG-interferon alfa-2b in patients with unresectable plexiform neurofibroma. (Dose escalation portion of study closed to accrual as of 2/2005.)
- Determine the toxicity profile of this drug in these patients.
Secondary
- Obtain, preliminary, information about the efficacy of this drug in these patients.
- Evaluate the growth rate of plexiform neurofibroma using volumetric MRI analysis in patients treated with this drug.
- Evaluate the impact of this drug, in terms of "worst symptom" score, in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT00085384M.D. Anderson Cancer Center30
终止
不适用
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCLLymphomaNCT00724061Northwestern University7
终止
1 期
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney CancerKidney CancerNCT00589550Thomas Olencki1
已完成
2 期
Interferon Alfa in Treating Children With HIV-Related CancerUnspecified Childhood Solid Tumor, Protocol SpecificLymphomaLeukemiaNCT00002621Children's Oncology Group8
终止
2 期
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00090870Medical University of South Carolina10